53 completed. 53 Phase 2, 12 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 53 | Completed 53 |
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 2 | Completed 2 |
Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 188 | 2019-05-23 | 2025-08-21 |
| Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas Pembrolizumab - Non-Hodgkin Lymphoma, Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2018-02-15 | 2023-11-28 |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) Zanubrutinib, Rituximab - Marginal Zone Lymphoma, Follicular Lymphoma | Phase 2 | Completed | BeiGene | 41 | 2018-01-04 | 2024-10-26 |
| Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma Zanubrutinib - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeiGene | 41 | 2017-06-30 | 2024-10-26 |
| Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma Tucidinostat - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Ou Bai, MD/PHD | 30 | 2017-06-01 | 2026-03-24 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Busulfan, Cyclophosphamide, Fludarabine Phosphate - Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 38 | 2017-05-30 | 2024-01-09 |
| A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Rituximab (RTX), Tafasitamab, Bendamustine (BEN) - Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Completed | Incyte Corporation | 453 | 2016-11-28 | 2025-07-17 |
| Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL Debio 1562, Rituximab - Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | Debiopharm International SA | 100 | 2016-06-05 | 2024-06-12 |
| RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma HS006+CHOP, Rituximab+CHOP - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Zhejiang Hisun Pharmaceutical Co. Ltd. | 137 | 2016-05-12 | 2018-04-02 |
| Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT Ibrutinib, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 64 | 2016-04-07 | 2024-10-10 |
| Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Tafasitamab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | MorphoSys AG | 81 | 2016-03-29 | 2023-10-23 |
| Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma R-CHOP - Diffuse Large B-cell Lymphoma, HIV | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 39 | 2016-03-01 | 2022-10-28 |
| An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma AZD 2014, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Birmingham | 36 | 2015-10-01 | 2020-11-05 |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Ibrutinib, MEDI4736 - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 61 | 2015-05-01 | 2019-06-27 |
| New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement Methotrexate, Rituximab, Cytarabine - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | International Extranodal Lymphoma Study Group (IELSG) | 79 | 2014-12-01 | 2025-07-08 |
| Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia Clofarabine, Mitoxantrone - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Completed | New York Medical College | 41 | 2013-03-01 | 2022-10-25 |
| Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse Rituximab, CMC544, Gemcitabine and Oxaliplatine - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | The Lymphoma Academic Research Organisation | 11 | 2012-12-01 | 2016-05-23 |
| Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy Bendamustine, Ofatumumab - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | SCRI Development Innovations, LLC | 22 | 2012-10-01 | 2017-11-22 |
| A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin - Follicular Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Genentech, Inc. | 231 | 2012-09-27 | 2020-02-21 |
| Erythropoietin for Management of Anemia Caused by Chemotherapy Darbepoetin alfa, R-CHOP - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Kosin University Gospel Hospital | 53 | 2012-09-01 | 2020-02-20 |
Showing 20 of 53. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (53) · Lymphoma (10) · Lymphoma, Mantle-Cell (8) · Lymphoma, Non-Hodgkin (6) · Lymphoma, Follicular (5) · Recurrence (4) · Burkitt Lymphoma (3) · Hodgkin Disease (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Multiple Myeloma (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
Hemic and Lymphatic Diseases (53) · Immune System Diseases (53) · Neoplasms (53) · Neoplasms by Histologic Type (53) · Immunoproliferative Disorders (52) · Lymphatic Diseases (52) · Lymphoproliferative Disorders (52) · Lymphoma, B-Cell (51) · Lymphoma, Non-Hodgkin (47) · Lymphoma (43) · Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Hematologic Diseases (5) · Leukemia (4)
Rituximab (26) · Cyclophosphamide (8) · Vincristine (8) · Doxorubicin (5) · Etoposide (5) · Prednisone (5) · Bendamustine Hydrochloride (4) · Gemcitabine (4) · Lenalidomide (4) · Oxaliplatin (4) · Ifosfamide (3) · Mitoxantrone (3) · Carmustine (2) · Clofarabine (2) · Cytarabine (2)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (4) · Millennium Pharmaceuticals, Inc. (3) · BeiGene (2) · Celgene (2) · Lymphoma Study Association (2) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (2) · Sanofi (2) · UNC Lineberger Comprehensive Cancer Center (2) · Acrotech Biopharma Inc. (1) · Amgen Research (Munich) GmbH (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · AstraZeneca (1) · City of Hope Medical Center (1) · Debiopharm International SA (1)
United States (24) · Italy (12) · Spain (12) · France (11) · United Kingdom (10) · Czechia (7) · Belgium (6) · Poland (6) · Germany (5) · Austria (4) · Hungary (4) · Israel (4) · Canada (3) · China (3) · Sweden (3)
Carlos Grande, MD (2) · Luis Palomera, MD (2) · Adrian Kilcoyne, MD (1) · Alejandro Martin (1) · Alessandro Levis, MD (1) · Antonio Alcala, MD (1)
PMID 38775302, PMID 17242396, PMID 21482186, PMID 21495023, PMID 22882209, PMID 23144193, PMID 23247661, PMID 23834234, PMID 23955074, PMID 24625556, PMID 25361987, PMID 26232170, PMID 26373676, PMID 26755709, PMID 27209293, PMID 27282998, PMID 28219694, PMID 28381416, PMID 29748443, PMID 29903707, PMID 30082475, PMID 30935953, PMID 31073022, PMID 32079690, PMID 32511983, PMID 32705923, PMID 32770353, PMID 33513372, PMID 34022150, PMID 34156440, PMID 34196165, PMID 34433649, PMID 34779360, PMID 35674661, PMID 35861632, PMID 37485564, PMID 37646664, PMID 39319495, PMID 40641817, PMID 42832423
2014 (2), 2004 (1), 2008 (1), 2015 (1), K01TW009488 (1), P01CA078902 (1), P30CA015704 (1), R21CA180815 (1)